Search

Displaying results 2861 - 2870 of 10000 in total
  1. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

    Categories: Metabolic Side Effects of Drugs and Substances
  2. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    Intrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later … on in the small intestine.

  3. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. … Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.

  4. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    to provide passive immunization against RSV infection as an alternative means of protection. … Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeted against the extracellular domain of the respiratory syncytial virus (RSV) fusion (F) protein.

  5. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Synonyms: DL-prenylamine
  6. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth.

  7. Drug

    Setoperone

    go.drugbank.com/drugs/DB20520
    Experimental

    Setoperone has a monoisotopic molecular weight of 401.16 Da. … Setoperone is a small molecule drug. The usage of the INN stem '-perone' in the name indicates that Setoperone is a tranquillizer, neuroleptic, 4'-fluoro-4-piperidinobutyrophenone derivative.

    Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of Chemicals
  8. Drug

    Artesunate

    go.drugbank.com/drugs/DB09274
    ApprovedInvestigational

    [L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.

    Synonyms: AS
  9. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. … [A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.

    Synonyms: (+)-2,2'-(ethylenediimino)di-1-butanolCategories: Drugs for Treatment of Tuberculosis
  10. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … [A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.